OKYO Pharma (OKYO) Retained Earnings (2021 - 2026)
OKYO Pharma (OKYO) posted quarterly Retained Earnings of -$152.0 million for Q1 2026, down 6.26% year-over-year from -$162.1 million in Q1 2025, and down 4.37% quarter-over-quarter from -$145.6 million in Q3 2025.
OKYO Pharma (OKYO) Retained Earnings (2021 - 2026) Analysis & Trends
OKYO Pharma (OKYO) has reported Retained Earnings for 6 consecutive years, with -$152.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 6.26% year-over-year to -$152.0 million; the TTM figure through Mar 2026 stood at -$152.0 million (down 6.26% YoY), while the FY2026 annual figure was -$152.0 million, down 6.26% from the prior year.
- Retained Earnings declined to -$152.0 million in Q1 2026 per OKYO's latest filing, from -$145.6 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$112.4 million in Q1 2022 and bottomed at -$152.0 million in Q1 2026.
- Historically, Retained Earnings has averaged -$137.6 million across 5 years, with a median of -$142.8 million in 2024.
- Annual changes were most pronounced in 2024 — Retained Earnings decreased 13.39% — and 2025, when it slipped 0.28%.
- OKYO Pharma's Retained Earnings stood at -$112.4 million in 2022, then slipped by 19.65% to -$134.5 million in 2023, then dropped by 7.95% to -$145.2 million in 2024, then dropped by 0.28% to -$145.6 million in 2025, then declined by 4.37% to -$152.0 million in 2026.
- Business Quant data shows OKYO's Retained Earnings at -$152.0 million in Q1 2026, -$145.6 million in Q3 2025, and -$143.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 4.38 Bn |
| 10 | OKYO Pharma | 1.49 Bn | 1.49 Bn | - | -152.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -151.97 Mn |
| Sep 30, 2025 | -145.61 Mn |
| Mar 31, 2025 | -143.02 Mn |
| Sep 30, 2024 | -145.20 Mn |
| Mar 31, 2024 | -142.52 Mn |
| Sep 30, 2023 | -134.52 Mn |
| Mar 31, 2023 | -125.70 Mn |
| Mar 31, 2022 | -112.43 Mn |
| Mar 31, 2021 | -106.00 Mn |